Trial · NCT07890233
Efficacy of an LED Mask
NCT07890233, Not applicable, Enrolling by invitation, Therabody, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of an LED Mask. Trials, record NCT07890233. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07890233
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of an LED Mask
- NCT number
- NCT07890233
- Status
- Enrolling by invitation
- Phases
- Not applicable
- Enrollment
- 110 participants, estimated
- Lead sponsor
- Therabody, Inc.
- Conditions
- Fine Lines and Wrinkles, Skin Health, Skin Tone
- Interventions
- Light emitting diode treatment
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Expert Clinical Grading | From enrollment to the end of treatment at 12 weeks | Assessments will be performed by a trained clinical grader and skin attributes will be assessed using an Ordinal Scale of 0 to 9 (modified Griffiths scale) on all subjects' faces. Outcome measures include: Firmness, fine lines, wrinkles, skin sagginess, radiance/luminosity, skin texture/smoothness, dark spot, skin tone evenness, contour of the jawline, overal skin appearance |
| Primary | Subjective and objective tolerance to device use | From enrollment to the end of treatment at 12 weeks | Tolerance will be graded objectively through ratings performed by a clinical grader relating to erythema, dryness, and edema, rated on a 4-point scale (0 = none, 3 = severe intensity). Subjective tolerance will be graded by the participant relating to stinging, tingling, itching, and burning on a 4 point scale (0 = none; 3 = severe). |
| Primary | Cutometer | From enrollment to the end of treatment at 12 weeks | The cutometer measures the viscoelastic properties of the skin by measuring the skin's response to the application of a probe. The Cutometer MPA 580 (Courage and Khazaka, Germany) device will be set to 450 mbar of pressure with a 6 second run time (3 seconds on and 3 seconds off). The curves will result in curves of R0 (mm), R5 (arbitrary units) and R7 (arbitrary units). |
| Primary | VISIA-CR | From enrollment to the end of treatment at 12 weeks | The VISIA-CR is a clinical facial imaging system used to analyze skin conditions. Images are taken in a variety of positions (frontal, left and right profiles) in consistent lighting. Image analysis for fine lines/wrinkles, skin texture/roughness, dark spots/hyperpigmentation, pores and redness will be performed with the VISIA-CR software. |
| Primary | Digital Photography | From enrollment to the end of treatment at 12 weeks | Clinical photography involves analysis of high-resolution images taken at different angles (right profile, 45 degrees right, straight on, 45 degrees left and 90 degrees left) to compare in a side-by-side format at each time point. |
| Primary | Self-assessment questionnaire | From enrollment to the end of treatment at 12 weeks | Participants will complete their perceived experience and comfort of use. Skin benefits including: firmness, appearance of fine lines, wrinkles (depth and appearance), radiance, plumpness, evenness, texture, redness, pigmentation, oiliness, pore appearance, dark spots, tightness, sagginess, texture, blemishes, appearance, health, scars/imperfections. All questions are on a 6 point scale (strongly agree to strongly disagree) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07890233
GET https://conductscience.org/api/trials/v1/NCT07890233/registered